Headquartered in India, Dr Reddy’s is a global, vertically integrated pharmaceutical company with a presence across the value chain, producing and delivering safe, innovative, and high quality finished dosage forms, APIs and biological products.
Their products are marketed across the globe, with an emphasis on North America, Europe, India, Russia and other emerging markets. Dr Reddy's conduct NCE drug discovery research in the areas of metabolic disorders and cardiovascular indications at our research facilities in Atlanta (USA) and Hyderabad (India).
Through their Custom Pharmaceutical Services business unit, they provide drug substance and drug product development and manufacturing services on a proprietary basis.
Dr Reddys Laboratories Limited Unit 2 was opened in 1984 and occupies an area of approximately six hectares. There are six manufacturing blocks producing a number of APIs, the most important of which are Ciprofloxacin, Atorvastatin Calcium, Finasteride, and Ketorolac Tromethamine.
Manufactures a number of APIs, including Cetirizine dihydrochloride, Losartan potassium and Clopidogrel bisulphate.
About the Audit
The audit of Dr Reddys Laboratories Limited Unit 2 site was performed on 28 - 29January 2008. The Report includes photographs and is 21 pages long, excluding appendices. Including appendices, the Report is 64 pages long.
The Audit Report provides information on the site facilities and covers a wide range of materials, including; Finasteride Form III, Ciprofloxacin, Atorvastatin Calcium, Finasteride, and Ketorolac Tromethamine.